Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Cancer immunotherapy in patients with brain metastases

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Exercise and cancer: from "healthy" to "therapeutic"?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. PD-L1-specific T cells

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Broadening the repertoire of melanoma-associated T-cell epitopes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Real-world evidence to guide healthcare policies in oncology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Peptide Super-Agonist Enhances T-Cell Responses to Melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Collagen density regulates the activity of tumor-infiltrating T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Michael Friedrich
  • Simon Jasinski-Bergner
  • Maria-Filothei Lazaridou
  • Karthikeyan Subbarayan
  • Chiara Massa
  • Sandy Tretbar
  • Anja Mueller
  • Diana Handke
  • Katharina Biehl
  • Jürgen Bukur
  • Marco Donia
  • Ofer Mandelboim
  • Barbara Seliger
Vis graf over relationer

Immunotherapy aims to activate the immune system to fight cancer in a very specific and targeted manner. Despite the success of different immunotherapeutic strategies, in particular antibodies directed against checkpoints as well as adoptive T-cell therapy, the response of patients is limited in different types of cancers. This attributes to escape of the tumor from immune surveillance and development of acquired resistances during therapy. In this review, the different evasion and resistance mechanisms that limit the efficacy of immunotherapies targeting tumor-associated antigens presented by major histocompatibility complex molecules on the surface of the malignant cells are summarized. Overcoming these escape mechanisms is a great challenge, but might lead to a better clinical outcome of patients and is therefore currently a major focus of research.

OriginalsprogEngelsk
TidsskriftCancer immunology, immunotherapy : CII
ISSN0340-7004
DOI
StatusE-pub ahead of print - 3 aug. 2019

ID: 57730672